Atractylenolide III reduces NLRP3 inflammasome activation and Th1/Th2 imbalances in both in vitro and in vivo models of asthma
- 20 March 2020
- journal article
- research article
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 47 (8), 1360-1367
- https://doi.org/10.1111/1440-1681.13306
Abstract
Pediatric asthma is a common inflammatory disease in children. Atractylenolide III is an active component of the Atractylodes rhizome, an herbal medicine that has been used as an asthma treatment. This study aimed to explore the effects and underlying mechanisms of atractylenolide III in IL‐4‐induced 16HBE cells and ovalbumin induced asthmatic mice. The results showed that IL‐4 stimulation significantly decreased, and atractylenolide III treatment increased, growth and apoptosis of 16HBE cells. In 16HBE cells, administration of atractylenolide III also significantly suppressed the IL‐4‐induced increases in the expression of cleaved caspase‐1; apoptosis‐associated speck‐like protein containing a caspase recruitment domain (ASC); and nucleotide‐binding domain and leucine‐rich repeat protein 3 (NLRP3). Moreover, the numbers of total leukocytes, neutrophils, eosinophils, and macrophages significantly increased in ovalbumin‐induced mice, and then decreased after atractylenolide III treatment. In ovalbumin‐induced asthmatic mice, atractylenolide III treatment also significantly inhibited NLRP3 inflammasome activation and restored the Th1/Th2 balance. These results indicate that atractylenolide III reduced NLRP3 inflammasome activation and regulated the Th1/Th2 balance in IL‐4 induced 16HBE cells and ovalbumin‐induced asthmatic mice, suggesting it has a protective effect that may be useful in the treatment of pediatric asthma.Keywords
This publication has 28 references indexed in Scilit:
- Protective effect of forsythiaside A on OVA-induced asthma in miceEuropean Journal of Pharmacology, 2017
- Efficacy and safety of inhaled corticosteroids relative to fluticasone propionate: a systematic review of randomized controlled trials in asthmaExpert Review of Respiratory Medicine, 2017
- Role for NLRP3 Inflammasome–mediated, IL-1β–Dependent Responses in Severe, Steroid-Resistant AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2017
- Asthma Exacerbations: Pathogenesis, Prevention, and TreatmentThe Journal of Allergy and Clinical Immunology: In Practice, 2017
- Evolution of Th2 responses: characterization of IL-4/13 in sea bass (Dicentrarchus labrax L.) and studies of expression and biological activityScientific Reports, 2017
- Revisiting Type 2‐high and Type 2‐low airway inflammation in asthma: current knowledge and therapeutic implicationsClinical and Experimental Allergy, 2017
- Atractylenolide III Enhances Energy Metabolism by Increasing the SIRT-1 and PGC1α Expression with AMPK Phosphorylation in C2C12 Mouse Skeletal Muscle CellsBiological & Pharmaceutical Bulletin, 2017
- Efficacy and Pharmacology of the NLRP3 Inflammasome Inhibitor CP-456,773 (CRID3) in Murine Models of Dermal and Pulmonary InflammationThe Journal of Immunology, 2016
- The Suppressive Effects of the Petroleum Ether Fraction fromAtractylodes lancea(Thunb.) DC. On a Collagen-Induced Arthritis ModelPhytotherapy Research, 2016
- Immunolocalization of NLRP3 Inflammasome in Normal Murine Airway Epithelium and Changes following Induction of Ovalbumin-Induced Airway InflammationJournal of Allergy, 2012